Alteplase: descendancy in myocardial infarction, ascendancy in stroke

Bibliography

• THE GISSI INVESTIGATORS: Effectiveness of intravenous thrombolytic treatment in acute MI. Gruppo Italian° per lo Studio della Streptochinasi nell'Infarto Miocardico (GISSI). Lancet (1986) 1:397–402.
   Google Scholar
• FRANZOSI MG, SANTORO E, DEVITA C et al.: Ten-year follow-up of the first megatrial testing thrombolytic therapy in patients with acute MI: results of the Gruppo Italian° per lo Studio della sophravvivenza nell'Infarto-1 study. The GISSI Investigators. Circulation (1998) 98:2659–2665.
   PubMed Web of Science ®Google Scholar
• CHESBRO JH, KNATTERUD G, ROBERTS R et al: Thrombolysis in MI (TIMI) Trial, Phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation (1987) 76:142–154.
   PubMed Web of Science ®Google Scholar
• WILCOX RG, VON DER LIPPE G, OLSSON CG etal.: Trial of tissue plasminogen activator of mortality reduction in acute MI. Anglo-Scandinavian Study of Early Thrombolysis (ASSET). Lancet (1988) 2:525–530.
   Google Scholar
• WILCOX RG, VON DER LIPPE G, OLSSON CG eta].: Effects of alteplase in acute MI: 6-month results from the ASSET study. Anglo-Scandinavian Study of Early Thrombolysis. Lancet (1990) 335:1175–1178.
   Google Scholar
• THE GISSI-2 INVESTIGATORS: GISSI-2:a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute MI. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. Lancet (1990) 336:65–71.
   Google Scholar
• THE INTERNATIONAL STUDY GROUP: In-hospital mortality and clinical course of 20,891 patients with suspected acute MI randomised between alteplase and streptokinase with or without heparin. Lancet (1990) 336:71–75.
   PubMed Web of Science ®Google Scholar
• THE LATE INVESTIGATORS: Late Assessment of Thrombolytic Efficacy (LATE) study with alteplase 6-24 hours after the onset of acute MI. Lancet (1993) 342:759–766.
   PubMed Web of Science ®Google Scholar
• STEINBERG JS, HOCHMAN JS, MORGAN et al.: Effects of thrombolytic therapy administered 6 to 24 hours after MI on the signal-averaged ECG. Results of a multicenter randomised trial. LATE Ancillary Study Investigators. Late Assessment of Thrombolytic Efficacy. Circulation (1994) 90:746–752.
   Google Scholar
• LANGER A, GOODMAN SG, TOPOL EJ etal.: Late assessment of thrombolytic efficacy (LATE) study: prognosis in patients with non-Q wave MI. (LATE Study Investigators) I Am. Coll. Cordial. (1996) 27:1327–1332.
   Google Scholar
• BECKER RC, CHARLESWORTH A, WILCOX RG et al: Cardiac rupture associated with thrombolytic therapy: impact of time to treatment in the Late Assessment of Thrombolytic Efficacy (LATE) Study. Am. Coll. Cardiol (1995) 25:1063–1068.
   PubMed Web of Science ®Google Scholar
• THE GUSTO ANGIOGRAPHIC INVESTIGATORS: The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute MI. N Engl. J. Med. (1993) 329:1515–1622.
   Web of Science ®Google Scholar
• THE GUSTO INVESTIGATORS, GLOBAL UTILISATION OF STREPTOKINASE AND TISSUE PLASMINOGEN ACTIVATOR FOR OCCLUDED CORONARY ARTERIES: Mortality within 24 hours of thrombolysis for MI. Circulation (1994) 90:2658–2665.
   PubMed Web of Science ®Google Scholar
• CALIFF RM, WHITE HD, VAN DE WERF F et al: One-year results from the Global Utilisation of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) trial. GUSTO-I Investigators. Circulation (1996) 94:1233–1238.
   PubMed Web of Science ®Google Scholar
• NEWBY LK, RUTSCH WR, CALIFF RIVI et al.: Time from symptom onset to treatment and outcomes after thrombolytic therapy. GUSTO-1 Investigators. J. Am. Coll. Cordial. (1996) 27:1646–1655.
   Google Scholar
• SIMES RJ, TOPOL EJ, HOLMES DR JR etal.: Link between the angiographic substudy and mortality outcomes in a large randomised trial of myocardial reperfusion. Importance of early and complete infarct artery reperfusion. GUSTO-I Investigators. Circulation (1995) 91:1923–1928.
   Google Scholar
• BAARDMAN T, HERMENS WT, LENDERINK T etal.: Differential effects of tissue plasminogen activator and streptokinase on infarct size and on rate of enzyme release: influence of early infarct related artery patency. The GUSTO Enzyme Substudy. Eur. Heart J. (1996) 17:237–246.
   Google Scholar
• GOLDBERG RJ, MOORADD M, GURWITZ JH etal.: Impact of time to treatment with tissue plasminogen activator on morbidity and mortality following acute MI (The second National Registry of Myocardial Infarction). Am. I Cordial. (1998) 82:259–264.
   Google Scholar
• NEUHAUS KL, TEBBE U, GOTTWIK M et al.: Intravenous recombinant tissue plasminogen activator (rt-TA) and urokinase in acute MI: results of the German Activator Urokinase Study (GAUS). J. Am. Coll. Cardiol (1988) 12:581–587.
   PubMed Web of Science ®Google Scholar
• NEUHAUS KL, VON ESSEN R, TEBBE U etal.: Improved thrombolysis in acute MI with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS). J. Am. Coll. Cordial. (1992) 19:885–891.
   Google Scholar
• CANNON CP, MCCABE CH, DIVER DJ etal.: Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute MI: results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial. J. Am. Coll. Cordial. (1994) 24:1602–1610.
   Google Scholar
• ••Trial demonstrating the benefits of front-loading alteplase.
   Google Scholar
• GULBA DC, TANSWELL E DECHEND R et al: Sixty-minute alteplase protocol: a new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute MI. j Am. Coll. Cardiol (1997) 30:1611–1617.
   PubMed Web of Science ®Google Scholar
• THE COBALT INVESTIGATORS: A comparison of continuous infusion of alteplase with double-bolus administration for acute MI. The Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators. N Engl. J. Med. (1997) 336:1124–1130.
   Google Scholar
• BLEICH SD, ADGEY AA, MCMECHAN SR, LOVE TW: An angiographic assessment of alteplase: double-bolus and front-loaded infusion regimens in MI. DouBLE Study Investigators. Double Bolus Lysis Efficacy. Am. Heart J. (1998) 136:741–748.
   Google Scholar
• GRINES CL, BROWNE KF, MARCO J et al.: A comparison of immediate angioplasty with thrombolytic therapy for acute MI. The Primary Angioplasty in Myocardial Infarction Study Group. N Engl. j Med. (1993) 328:673–679.
   Google Scholar
• STONE GW, GRINES CL, BROWNE KF etal.: Implications of recurrent ischaemia after reperfusion therapy in acute MI: a comparison of thrombolytic therapy and primary angioplasty. j Am. Coll. Cordial. (1995) 26:66–72.
   Google Scholar
• STONE GW, GRINES CL, BROWN KF et al.: Influence of acute MI location on in-hospital and late outcome after primary percutaneous transluminal coronary angioplasty versus tissue plasminogen activator therapy. Am. j Cordial. (1996) 78:19–25.
   PubMed Web of Science ®Google Scholar
• STONE GW, GRINES CL, BROWNE KF etal.: Outcome of different reperfusion strategies in patients with former contraindications to thrombolytic therapy: a comparison of primary angioplasty and tissue plasminogen activator. Primary Angioplasty in Myocardial Infarction (PAMI) Investigators. Gotha. Cardiovasc. Diagn. (1996) 39:333–339.
   Google Scholar
• NUNN CM, O'NEILL WW, ROTHBAUM D etal.: Long-term outcome after primary angioplasty: report from the primary angioplasty in MI (PAMI-I) trial. j Am. Coll. Cordial. (1999) 33:640–646.
   Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES IN ACUTE CORONARY SYNDROMES (GUSTO IIb) ANGIOPLASTY SUBSTUDY INVESTIGATORS: A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute MI. N. Engl. J. Med. (1997) 335:1621–1628.
   Google Scholar
• HOLMES DR JR, WHITE HD, PIEPER KS et al.: Effect of age on outcome with primary angioplasty versusthrombolysis. Ain. Coll. Cardiol (1999) 33:412–419.
   PubMed Web of Science ®Google Scholar
• RIBICHINI F, STEFFENINO G, DELLAVALLE A et al: Comparison of thrombolytic therapy and primary coronary angioplasty with liberal stenting for inferior MI with precordial ST-segment depression: immediate and long-term results of a randomised study. j Am. Coll. Cordial. (1998) 32:1678–1694.
   Web of Science ®Google Scholar
• GARCIA E, ELIZAGA J, PEREZ-CASTELLANO N et al: Primary angioplasty versus systemic thrombolysis in anterior MI. J. Am. Coll. Cardiol (1999) 33:605–611.
   PubMed Web of Science ®Google Scholar
• SCHOMIG A, KASTRATI A, DIRSCHINGER J et al.: Coronary stenting plus glycoprotein IIb/IIIa blockade compared with tissue plasminogen activator in acute MI. Stent versus Thrombolysis for Occluded Coronary Arteries in Patients with Acute Myocardial Infarction Study Investigators. N Engl. J. Med. (2000) 10:385–391.
   Google Scholar
• LE MAY MR, LABINAZ M, RICHARD FA et al.: Stenting versus thrombolysis in acute MI trial (STATL J. Am. Coll. Cordial. (2001) 37:985–991.
   PubMed Web of Science ®Google Scholar
• VERHEUGT FW, MEIJER A, LAGRAND WK, VAN EENIGE MJ: Reocclusion: the flip side of coronary thrombolysis. j Am. Coll. Cordial. (1996) 15:766–773.
   Web of Science ®Google Scholar
• WILSON SH, BELL MR, RIHAL CS et al:Infarct artery reocclusion after primary angioplasty, stent replacement and thrombolytic therapy for acute MI. Am. HeartJ (2001) 141:704–710.
   PubMed Web of Science ®Google Scholar
• THE TIMI STUDY GROUP: Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute MI. Result of the thrombolysis in MI (TIMI) Phase II trial. The TIMI Study Group. N Engl. J. Med. (1989) 320:618–627.
   Google Scholar
• ROSS AM, COYNE KS, REINER JS et al:A randomised trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute MI: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial. J. Am. Coll. Cardiol (1999) 34:1954–1962.
   PubMed Web of Science ®Google Scholar
• BROTT TG, HALEY EC JR, LEVY DE et al.: Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 min. Stroke (1992) 23:632–640.
   Google Scholar
• HALEY EC JR, LEVY DE, BROTT TG et al.: Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91–180 minutes from onset. Stroke (1992) 23:641–645.
   Google Scholar
• HALEY EC, BROTT TG, SHEPPARD GL et al: Pilot randomised trial of tissue plasminogen activator in acute ischaemic stroke. The TPA Bridging Study Group. Stroke (1993) 24:1000–1004.
   Google Scholar
• HACKE W, KASTE M, FIESCHI C et al:Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). JAMA (1995) 274:1017–1025.
   Google Scholar
• PANTANO P, CARAMIA F, BOZZAO L, DIELER C, VON KUMMER R: Delayed increase in infarct volume after cerebral ischaemia: correlation with thrombolytic treatment and clinical outcome. Stroke (1999) 30:502–507.
   PubMed Web of Science ®Google Scholar
• MANELFE C, LARRUE V, VON KUMMER R etal.: Associate of hyperdense middle cerebral artery sign with clinical outcome in patients treated with tissue plasminogen activator. Stroke (1999) 30: 769–772.
   Google Scholar
• STEINER T, BLUHMKI E, KASTE M et al.: The ECASS 3-hour cohort. Secondary analysis of ECASS by time stratification. ECASS Study Group. European Cooperative Acute Stroke Study. Cerebrovasc. Dis. (1998) 8:198–203.
   Google Scholar
• HACKE W, BLUHMKI E, STEINER T et al.: Dichotomised efficacy endpoints and global end-point analysis to the ECASS intention-to-treat data set: post hoc analysis of ECASS I. Stroke (1998) 29:2073–2075.
   PubMed Web of Science ®Google Scholar
• HACKE W, KASTE M, FIESCH C et al:Randomised double blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet (1998) 17:1245–1251.
   Google Scholar
• THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE RT-PA STROKE STUDY GROUP: Tissue plasminogen activator for acute ischaemic stroke. N Engl. J. Med. (1995) 333:1581–1587.
   PubMed Web of Science ®Google Scholar
• THE NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE RT-PA STROKE STUDY GROUP: Generalised efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Strole Trial. Stroke (1997) 28:2119–2125.
   PubMed Web of Science ®Google Scholar
• GROTTA JC, ALEXANDROV AV: t-PA-associated reperfusion after acute stroke demonstrated by SPECT. Stroke (1998) 29:429–432.
   PubMed Web of Science ®Google Scholar
• KWIATKOWSKI TG, LIBMAN RB, FRANKEL M et al: Effects of tissue plasminogen activator for acute ischaemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl. J. Med. (1999) 340:1781–1787.
   Google Scholar
• MARLER JR, TILLEY BC, LU M et al.: Early stroke treatment associated with better outcome: the NINDS rtPA stroke study. Neurology (2000) 55:1649–1655.
   PubMed Web of Science ®Google Scholar
• GROND M, STENZEL C, SCHMULLING S et al: Early intravenous thrombolysis for acute ischaemic stroke in a community-based approach. Stroke (1998) 29:1544–1549.
   PubMed Web of Science ®Google Scholar
• SCHMULLING S, GROND M, RUDOLF J, HEISS WD: One-year follow-up in acute stroke patients treated with rtPA in clinical routine. Stroke (2000) 31:1522–1524.
   Web of Science ®Google Scholar
• TANNE D, BATES VE, VERRO P et al: Initial clinical experience with IV tissue plasminogen activator for acute ischaemic stroke: a multicenter survey. The t-PA Stroke Survey Group. Neurology (1999) 53:424–427.
   Google Scholar
• ALBERS GW, BATES VE, CLARK WM et al.: Intravenous tissue-type plasminogen activator for treatment of acute stroke: the Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA (2000) 9:1145–1150.
   Web of Science ®Google Scholar
• KATZAN IR, FURLAN AJ, LYOYD LE et al.: Use of tissue-type plasminogen activator for acute ischaemic stroke. The Cleveland Area Experience. JAMA (2000) 9:1151–1158.
   Google Scholar
• CLARK WM, WISSMAN S, ALBERS SW et al: Recombinant tissue-type plasminogen activator (Alteplase) for ischaemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomised controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in ischaemic Stroke. JAMA (1999) 282:2019–2026.
   Google Scholar
• CLARK WM, ALBERS GW, MADDEN KPet al: The rtPA (alteplase) 0-to 6-hour trial, part A (A0276g): results of a double blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischaemic stroke study investigators. Stroke (2000) 31:811–816.
   PubMed Web of Science ®Google Scholar
• UEDA T, HATAKEYAMA T, KUMON Y, SAKAKI S et al: Evaluation of risk of haemorrhagic transformation in local intra-arterial thrombolysis in acute ischaemic stroke by initial SPECT. Stroke (1994) 25:298–303.
   PubMed Web of Science ®Google Scholar
• QURESHI Al, SURI MF, SHATLA AA etal.: Intraarterial recombinant tissue plasminogen activator for ischaemic stroke: an accelerating dosing regimen. Neurosurgery (2000) 47:473–476.
   Google Scholar
• LEWANDOWSKI CA, FRANKEL M, TOMSICK TA et al: Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischaemic stroke: Emergency Management of Stroke (EMS) Bridging Trial. Stroke (1999) 30:2598–2605.
   PubMed Web of Science ®Google Scholar
• ERNST R, PANCIOLI A, TOMSICK T et al.: Combined intravenous and intra-arterial recombinant tissue plasminogen activator in acute ischaemic stroke. Stroke (2000) 31:2552–2557.
   PubMed Web of Science ®Google Scholar
• FREY JL, MURO GJ, MCDOUGALL CG, DEAN BL, JAHNKE HK: Cerebral venous thrombosis: combined intrathrombus rtPA and intravenous heparin. Stroke (1999) 30:489–494.
   PubMed Web of Science ®Google Scholar
• NICKLAS JM, TOPOL EJ, KANDER N et al.: Randomised, double blind, placebo-controlled trial of tissue plasminogen activator in unstable angina. J. Am. Coll. Cardiol (1989) 13:434–441.
   PubMed Web of Science ®Google Scholar
• THROMBOLYSIS IN MYOCARDIAL ISCHEMIA (TIMI IIIA) TRIAL INVESTIGATORS: Early effects of tissue-type plasminogen activator added to conventional therapy on the culprit coronary lesion in patients presenting with ischaemic pain at rest. Results of the Thrombolysis in Myocardial ischaemia (TIMI IIIA Circulation (1993) 87:38–52.
   PubMed Web of Science ®Google Scholar
• THROMBOLYSIS IN MYOCARDIAL ISCHEMIA (TIMI IIIB) TRIAL INVESTIGATORS: Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q wave MI: results of the TIMI IIIB trial. Circulation (1994) 89:1545–1556.
   PubMed Web of Science ®Google Scholar
• ANDERSON HV, CANNON CI STONE PH et al.: One-year results of the Thrombolysis in Myocardial ischaemia (TIMI) IIIB clinical trial. A randomised comparison of tissue-type plasminogen activator versus placebo and early invasive versus early conservative strategies in unstable angina and non-Q wave MI. I Am. Coll. Cardial (1995) 26:1643–1650.
   Google Scholar
• ROMEO F, ROSANO GM, MARTUSCELLI E et al.: Effectiveness of prolonged low dose recombinant tissue-type activator for refractory unstable angina. I Am. Coll Cardial (1995) 25:1295–1299.
   PubMed Web of Science ®Google Scholar
• GOLDHABER SZ, KESSLER CM, HEIT Jet al.: Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet (1988) 2:293–298.
   Google Scholar
• MEYER G, SORS H, CHARBONNIER B et al.: Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. The European Cooperative Study Group for Pulmonary Embolism. I Am. Coll Cardial (1992) 19:239–245.
   PubMed Web of Science ®Google Scholar
• DALLA-VOLTA S, PALLA A, SANTOLICANDRO A et al: PAIMS 2: alteplase combined with heparin versus heparin in the treatment of acute pulmonary embolism. Plasminogen activator Italian multicenter study 2.1 Am. Coll Cardial. (1992) 20:520–526.
   Google Scholar
• GOLDHABER SZ, HAIRE WD, FELDSTEIN ML etal.: Alteplase versus heparin in acute pulmonary embolism: randomised trial assessing right-ventricular function and pulmonary perfusion. Lancet (1993) 27:507–511.
   Google Scholar
• SORS H, PACOURET G, AZARIAN R et al.: Hemodynamic effects of bolus vs. 2-h infusion of alteplase in acute massive pulmonary embolism. A randomised controlled multicenter trial. Chest (1994) 106:712–717.
   Google Scholar
• GOLDHABER SZ, AGNELLI G, LEVINE MN: Reduced dose bolus alteplase vs. conventional alteplase infusion for pulmonary embolism thrombolysis. An international multicenter randomised trial. The Bolus Alteplase Pulmonary Embolism Group. Chest (1994) 106:718–724.
   Google Scholar
• MENEVEAU N, SCHIELE F, VUILLEMENOT A et al: Streptokinase vs. alteplase in massive pulmonary embolism. A randomised trial assesses right heart haemodynamics and pulmonary vascular obstruction. Eur. Heart J. (1997) 18:1141–1148.
   Google Scholar
• MENEVEAU N, SCHIELE F, METZ D et al.: Comparative efficacy of a two-hour regimen of streptokinase versus alteplase in acute massive pulmonary embolism: immediate clinical and hemodynamic outcome and one-year follow-up. I Am. Coll Cardial. (1998) 31:1057–1063.
   PubMed Web of Science ®Google Scholar
• TURPIE AG, LEVINE MN, HIRSCH J et al.: Tissue plasminogen activator (ft-PA) vs. heparin in deep vein thrombosis. Results of a randomised trial. Chest (1990) 97:172S–175S.
   Google Scholar
• GOLDHABER SZ, MEYEROVITZ MF, GREEN D et al.: Randomised controlled trial of tissue plasminogen activator in proximal deep venous thrombosis. Am. 1 Med. (1990) 88:235–240.
   Google Scholar
• BOUNAMEAUX H, BANGA JD, BLUHMKI E et al.: Double-blind, randomised comparison of systemic continuous infusion of 0.25 versus 0.50 mg/ kg/24 h of alteplase over 3 to 7 days for treatment of deep venous thrombosis in heparinized patients: results of the European Thrombolysis with ft-PA in Venous Thrombosis (ETTT) trial. Thromb. Haemost. (1992) 67:306–309.
   Google Scholar
• SCHWIEDER G, GRIMM W, SIEMENS HJ et al.: Intermittent regional therapy with rt-PA is not superior to systemic thrombolysis in deep vein thrombosis (DVT)-a German multicenter trial. Thromb. Haemost. (1995) 74:1240–1243.
   PubMed Web of Science ®Google Scholar
• FORSTER A, WELLS P: Tissue plasminogen activator for the treatment of deep vein thrombosis of the lower extremity: a systematic review. Chest (2001) 119:572–579.
   PubMed Web of Science ®Google Scholar
• THE STILE INVESTIGATORS: Results of a prospective randomised trial evaluation surgery versus thrombolysis for ischaemia of the lower extremity. The STILE trial. Ann. Surg. (1994) 220:251–266.
   PubMed Web of Science ®Google Scholar
• WEAVER FA, COMEROTA AJ, YOUNGBLOOD M et al: Surgical revascularisation versus thrombolysis for nonembolic lower extremity native artery occlusions: results of a prospective randomised trial. The STILE Investigators. Surgery versus Thrombolysis for ischaemia of the Lower Extremity. I Vasc. Surg. (1996) 24:513–521.
   Google Scholar
• BERO CJ, CARDELLA JF, REDDY K etal.:Recombinant tissue plasminogen activator for the treatment of low extremity peripheral vascular occlusive disease. I Vasc. Interv. Radial. (1995) 6:571–577.
   Google Scholar
• HESS H, MIETASCHK A, VON BILDERLING P, NELLER P: Peripheral arterial occlusions: local low-dose thrombolytic therapy with recombinant tissue-type plasminogen activator (ft-PA). Eur. Vasc. Endovasc. Surg. (1996) 12:97–104.
   PubMed Web of Science ®Google Scholar
• COMEROTA AJ, WEAVER FA, HOSKING JD et al: Results of a prospective, randomised trial of surgery versus thrombolysis for occluded lower extremity bypass graft. Arta Surg. (1996) 172:105–112.
   PubMed Web of Science ®Google Scholar
• MEYEROVITZ MF, DIDIER D, VOGEL JJ, SOULIER-PARMEGGIANI L, BOUNAMEAUX H: Thrombolytic therapy compared with mechanical recanalisation in non-acute peripheral arterial occlusions: a randomised trial. 1 Vasc. Interv. Radial (1995) 6:775–781.
   Google Scholar
• BRAITHWAITE BD, BUCKENHAM TM, GALLAND RB, HEATHER BP, EARNSHAW JJ: Prospective randomised trial of high-dose bolus versus low-dose tissue plasminogen activator infusion in the management of acute limb ischaemia. Thrombolysis Study Group. Br I Surg. (1997) 84:646–650.
   PubMed Web of Science ®Google Scholar
• HAIRE WD, ATKINSON JB, STEPHENS LC, KOTULAK GD: Urokinase versus recombinant tissue plasminogen activator in thrombosed central venous catheters: a double blind, randomised trial. Thromb. Haemost. (1994) 72:543–547.
   PubMed Web of Science ®Google Scholar